UNSPSC 51121919: Etomoxir

This classification denotes an enzyme inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MSB3DD2XP6. European Medicines Agency schedules Etomoxir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07332MIG. Etomoxir generally arises in the molecular formula C17H23CLO4. The term ETOMOXIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) Most nations schedule etomoxir under HS 29189900 and SITC 51396.

As of Q4 2014, ETOMOXIR remains the US FDA Preferred Term for this commodity. Etomoxir bears US NLM identifiers UMLS ID C0059872 and NCI Concept Code C81111. SMILES: CLC1CCC(OCCCCCCC2(OC2)C(=O)OCC)CC1.

UNSPSC 51121919 Etomoxir, a Commodity-tier code, captures state and local procurement of specialized pharmaceuticals and advanced life support medications for emergency medical services, hospital systems, and public health programs. Recent solicitations show state and local buyers sourcing individual medication line items—including epinephrine, labetalol, adenosine, and diltiazem—alongside broader generic pharmaceutical and over-the-counter product frameworks. The work spans direct supply of finished medications to fire rescue services, cooperative purchasing agreements for multi-source generics distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer pharmacy initiatives. Issuing bodies include city purchasing departments (Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Vendors typically must meet FDA compliance, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, maintain expiration-date minimums (commonly nine months to one year from acceptance), provide Safety Data Sheets compliant with OSHA Hazard Communication Standards, and in some cases demonstrate electronic data interchange (EDI) capability and network security insurance.

The code shows recent activity across Texas, Minnesota, Florida, and Oregon through cooperative purchasing vehicles and individual municipal solicitations. The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000—a one-year term with two optional one-year renewals and unilateral extension rights for up to three additional 30-day periods, with a 5 percent bid discount available to Small Local Business Enterprises not to exceed $10,000. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for Generic Multi-Source Pharmaceuticals and OTC Products with a response deadline of March 26, 2026, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and pay a 3 percent administrative fee on all purchases. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs supporting negotiated net pricing and value-based agreements, with no award value identified in this preliminary information-gathering phase.